Home Cart Sign in  
Chemical Structure| 1187431-43-1 Chemical Structure| 1187431-43-1

Structure of Trametinib (DMSO solvate)
CAS No.: 1187431-43-1

Chemical Structure| 1187431-43-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM, activating autophagy and inducing apoptosis.

Synonyms: GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate); Trametinib dimethyl sulfoxide

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Kaustav Khatua ; Yugendar R. Alugubelli ; Kai S. Yang ; Veerabhadra R. Vulupala ; Lauren R. Blankenship ; Demonta Coleman , et al.

Abstract: The main (MPro) of SARS-CoV-2, the causative agent of COVID-19, is a pivotal nonstructural critical for viral replication and pathogenesis. Its function relies on three active site pockets for substrate recognition and a catalytic for enzymatic activity. To develop potential SARS-CoV-2 , we successfully synthesized a diverse range of azapeptide inhibitors with various covalent warheads to target MPro's catalytic . Our characterization identified potent MPro inhibitors, including MPI89 that features an aza-2,2-dichloroacetyl warhead with a remarkable EC50 value of 10 nM against SARS-CoV-2 infection in ACE2+ A549 cells and a selective index of 875. MPI89 is also remarkably selective and shows no potency against SARS-CoV-2 papain-like and several human proteases. Crystallography analyses demonstrated that these inhibitors covalently engaged the catalytic and used the aza-amide carbonyl oxygen to bind to the oxyanion hole. MPI89 stands as one of the most potent MPro inhibitors, suggesting the potential for further exploration of azapeptides and the aza-2,2-dichloroacetyl warhead for developing effective therapeutics against COVID-19.

Keywords: COVID-19 ; SARS-CoV-2 ; Main protease ; Azapeptide ; Covalent inhibitor

Purchased from AmBeed: ; ; ;

Alternative Products

Product Details of Trametinib (DMSO solvate)

CAS No. :1187431-43-1
Formula : C28H29FIN5O5S
M.W : 693.53
SMILES Code : O=C(N(C(C1=C(N2C)NC(C=CC(I)=C3)=C3F)=C(C)C2=O)C4=CC=CC(NC(C)=O)=C4)N(C1=O)C5CC5.O=S(C)C
Synonyms :
GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate); Trametinib dimethyl sulfoxide
MDL No. :MFCD21609250
InChI Key :OQUFJVRYDFIQBW-UHFFFAOYSA-N
Pubchem ID :50992434

Safety of Trametinib (DMSO solvate)

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Trametinib (DMSO solvate)

MAPK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293T cells 1 μM 2 h BRET experiments were conducted to measure the binding of Trametinib to MEK1 and KSR1. The results showed that Trametinib generated BRET signals with both MEK1 and KSR1, indicating that Trametinib can bind to MEK1 and KSR1. PMC7746607
CRC cells 25 nM 5 days To evaluate the effect of Trametinib in combination with JQ1 on CRC cell proliferation, results showed that the combination significantly inhibited cell proliferation PMC5368030
KRAS-mutant mouse LUAD cells 100 nM 72 h To evaluate the effect of Trametinib on cell growth, results showed that Trametinib significantly inhibited the proliferation of KRAS-mutant mouse LUAD cells. PMC11031964
KRAS-mutant human LUAD cells 500 nM 72 h To evaluate the effect of Trametinib on cell growth, results showed that Trametinib significantly inhibited the proliferation of KRAS-mutant human LUAD cells. PMC11031964
KRAS-wild type human LUAD cells 500 nM 72 h To evaluate the effect of Trametinib on cell growth, results showed that Trametinib had no significant effect on the proliferation of KRAS-wild type human LUAD cells, except for H1437 cells where inhibition was observed. PMC11031964
BBN963 cells 100 µM 72 h To evaluate the effect of Trametinib on apoptosis in BBN963 cells, results showed that Trametinib alone increased the number of cells in late apoptosis. PMC11297265
BBN963 cells 100 µM 72 h To evaluate the effect of Rosi+Tram combination on apoptosis in BBN963 cells, results showed that the combination further increased the number of cells in both early and late apoptosis. PMC11297265
TBP primary melanoma cells 1 nM 10 days To evaluate the effect of Trametinib on TBP primary melanoma cells in spheroid formation, results showed that Trametinib inhibited spheroid growth. PMC10478295
S462 cells 200 nM 24 h To evaluate the synergistic anti-proliferative activity of Trametinib in combination with Palbociclib on MPNST cells, the results showed that the combination therapy significantly reduced RB1 phosphorylation and increased cell death and senescence. PMC10528807

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
nude mice CRC xenograft model oral 0.5 mg/kg or 1 mg/kg once daily for 14 days To evaluate the effect of Trametinib in combination with JQ1 on CRC xenograft tumors, results showed that the combination significantly inhibited tumor growth PMC5368030
mice KRAS-mutant LUAD model oral 1 mg/kg 5 times a week until day 30 To evaluate the effect of Trametinib on tumor growth, results showed that Trametinib significantly reduced the volumes of CMT167 and LLC tumors and downregulated Id1 expression in tumor tissues. PMC11031964
Mice BBN-induced BASQ bladder cancer model Oral 0.3 mg/kg Daily for 1 month To evaluate the effect of Trametinib alone and in combination with Rosiglitazone on BBN-induced BASQ tumors, results showed that the combination induced apoptosis in tumor cells and reduced tumor volume by 91% within one month. PMC11297265
Mice Pancreatic cancer model Oral 1 mg/kg 4 consecutive days followed by 3 days off To evaluate the effect of Trametinib on pancreatic cancer model PMC9701143
Mice Braf-mutant melanoma model Oral 1 mg/kg Daily administration for 5 weeks To evaluate the effect of Trametinib in combination with Dabrafenib on Braf-mutant melanoma models, results showed that the combination therapy significantly inhibited tumor growth and delayed the onset of resistance. PMC10478295
NOD-SCID mice QGP-1 xenograft model Oral 1 mg/kg 2 weeks (5 days of drug treatment and 2 days of rest) Trametinib suppressed the enhanced invasion capability of QGP-1 xenograft tumors with PTEN loss, but did not significantly inhibit tumor growth. PMC9639322
Mice Immune-deficient mouse model Oral 0.075 mg/kg Daily administration for 5 days, followed by 2 days off To evaluate the anti-tumor activity of Trametinib in combination with Ribociclib in MPNST PDX models, the results showed that the combination therapy exhibited synergistic anti-tumor activity in some PDX models. PMC10528807

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.44mL

0.29mL

0.14mL

7.21mL

1.44mL

0.72mL

14.42mL

2.88mL

1.44mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories